Walmart Expands into GLP-1 Drug Access
The story in brief
Walmart is expanding its role in the prescription market by offering GLP-1 weight-loss drugs directly to consumers through programs like LillyDirect, which charges $299 to $449 monthly. The move, driven by direct-to-consumer access, positions Walmart to compete with CVS and Walgreens, while also drawing Amazon into the healthcare space. Independent pharmacies face challenges as major retailers gain access to these drugs.